Floatz logo

Quizartinib

Blasts More Than 10 Percent of Bone Marrow Nucleated Cells

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Blasts More Than 10 Percent of Bone Marrow Nucleated Cells cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
University of Southern California
Phase 3BBB
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Quizartinib is also rated in:

myelodysplastic syndromeDormant
BB
Indicative ·
67 / 100
View asset →
acute myeloid leukemia, FLT3 internal tandem duplicationDormant
BB
Indicative ·
64 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →